Pattern of disease recurrence and outcomes after progression of high-risk renal cell carcinoma (RCC) patients treated with adjuvant immunotherapy
High-risk RCC patients treated with adjuvant immunotherapy remain at considerable risk of relapse, frequently with oligometastatic disease. Excellent post-progression outcomes after loco-regional treatment support a multidisciplinary, metastasis-directed approach to recurrence after adjuvant immunotherapy.
Authors
- Romina Rose Pedone (ORCID: https://orcid.org/0000-0001-5159-5604)
- Alessio Neri
- Chiara Ligato
- Gloria Messina
- Valeria Sardaro
- Denis Occhipinti (ORCID: https://orcid.org/0000-0003-0667-5458)
- Daniela Arduini (ORCID: https://orcid.org/0000-0002-0624-9814)
- Luca Tagliaferri (ORCID: https://orcid.org/0000-0003-2308-0982)
- Rachele Belletto
- Rexhina Ajdhoni
- Paola Troisi
- Luigi Roca
- Maria Antonia Fucile
- Chiara CICCARESE
- Giampaolo Tortora
- Bernardo Rocco
- Davide Di Leo
- Roberto Iacovelli
- Fabiana Caliciotti
Institutions
- Università Cattolica del Sacro Cuore (IT)
- Agostino Gemelli University Polyclinic (IT)
- Istituti di Ricovero e Cura a Carattere Scientifico (IT)
Publication Details
- Journal
- Cancer Immunology Immunotherapy
- Published
- 2026-02-25
- DOI
- https://doi.org/10.1007/s00262-026-04331-0
- Primary Topic
- Renal cell carcinoma treatment
- Type
- article
- Field-Weighted Citation Impact
- 0.00